景峯醫藥(000908.SZ)子公司獲得知識產權管理體系認證證書
格隆匯11月19日丨景峯醫藥(000908.SZ)公佈,公司之全資子公司貴州景峯注射劑有限公司於近日收到中知(北京)認證有限公司頒發的《知識產權管理體系認證證書》,認證範圍:大容量注射劑(含中藥提取)、小容量注射劑、濃縮丸(含中藥提取)、凍乾粉針劑的研發、生產、銷售的知識產權管理;有效期至:2022年11月17日。
《企業知識產權管理規範》(GB/T29490-2013),是由國家知識產權局、中國標準化研究院起草,並由國家質量監督檢驗檢疫總局、國家標準化管理委員會發佈及實施,該規範旨在指導企業建立科學、系統的知識產權管理體系,全面保護並系統管理知識產權,有效提高企業靈活運用知識產權的能力和水平,促進企業的技術創新,提升企業的核心競爭力,保障企業的可持續發展。
此次《知識產權管理體系認證證書》的取得,標誌着貴州景峯注射劑有限公司的知識產權管理工作進入標準化、規範化、系統化管理的新高度,有利於提升公司的知識產權保護意識,促進自主創新,提高公司的市場競爭地位和核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.